A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis-Reference-Cited by-同舟云学术

A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis

Published:1991-12 Issue:6 Volume:25 Page:1145-1148
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Goldberg Barbara,Hartdegen Richard,Presbury David,Harvey Smith Eric,Yawalkar Shantaram

Publisher

Elsevier BV

Subject

Dermatology

Reference3 articles.

1. A double-blind multi-center comparison of 0.02% and 0.05% CGP 14 458 ointments and Dermovate ointment in patients with chronic psoriasis;Blum;Chin J Dermatol,1986

2. Topical treatment of psoriasis with corticosteroids;Maibach;Acta Derm Venereol,1984

3. Topical clobetasol 17-propionate: review of its clinical efficacy and safety;Olsen;J Am Acad Dermatol,1986

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis;Expert Review of Clinical Immunology;2022-08-08

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

;Clinical, Cosmetic and Investigational Dermatology;2020-06

3. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology;Journal of Dermatological Treatment;2019-09-26

4. Development of Halobetasol-loaded nanostructured lipid carrier for dermal administration: Optimization, physicochemical and biopharmaceutical behavior, and therapeutic efficacy;Nanomedicine: Nanotechnology, Biology and Medicine;2019-08

5. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis;Journal of Dermatological Treatment;2018-11-05